Analyst Price Targets — LONA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 18, 2026 9:40 pm | — | Mizuho Securities | $10.00 | $4.76 | TheFly | LeonaBio upgraded to Outperform from Neutral at Mizuho |
| September 19, 2025 11:02 am | Graig Suvannavejh | Mizuho Securities | $4.00 | $3.83 | TheFly | Athira Pharma price target lowered to $4 from $5 at Mizuho |
| June 22, 2022 6:52 pm | Andrew Tsai | Jefferies | $3.00 | $2.85 | TheFly | Athira Pharma downgraded to Hold from Buy at Jefferies |
| April 21, 2022 8:46 am | — | Berenberg Bank | $33.00 | $11.63 | Benzinga | Berenberg Initiates Coverage On Athira Pharma with Buy Rating, Announces Price Target of $33 |
Latest News for LONA
Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer Patients with ESR1-Mutations
Prime Medicine (NASDAQ: PRME - Get Free Report) and Athira Pharma (NASDAQ: LONA - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability. Risk and Volatility Prime Medicine has a
Athira Pharma (NASDAQ: LONA - Get Free Report) and Prime Medicine (NASDAQ: PRME - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, profitability, valuation and dividends. Earnings and Valuation This table compares Athira
Athira Pharma (NASDAQ: LONA - Get Free Report) and Liminatus Pharma (NASDAQ: LIMN - Get Free Report) are both small-cap manufacturing companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, profitability, earnings, analyst recommendations and risk. Earnings and Valuation This table compares Athira
Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Athira Pharma (NASDAQ: LONA - Get Free Report) are both small-cap manufacturing companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, earnings, institutional ownership and valuation. Valuation and Earnings This table compares Liminatus
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LONA.
U.S. House Trading
No House trades found for LONA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.